US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Estrella Immunopharma

0.9200

-0.0700-7.07%

Post-market: 0.92000.00000.00%17:59 EDT

Volume:11.61K

Turnover:11.07K

Market Cap:33.27M

PE:-3.79

High:0.9899

Open:0.9300

Low:0.8971

Close:0.9900

Loading ...

Overview Company News Filings

Estrella Immunopharma Partners with Baylor Research Institute to Expand STARLIGHT-1 Trial for B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma Announces Activation of Additional Site for Phase I/Ii Starlight-1 Trial in B-Cell Non-Hodgkin’s Lymphoma

THOMSON REUTERS

Estrella Immunopharma Is Maintained at Buy by D. Boral Capital

Estrella Immunopharma Secures $3.35 Million Through Private Equity Placement to Advance Cancer Therapy Trials

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

THOMSON REUTERS

Estrella Immunopharma Is Maintained at Buy by D. Boral Capital

Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in Starlight-1 Trial of Eb103 in Advanced B-Cell Non-Hodgkin’s Lymphomas

THOMSON REUTERS

Estrella Immunopharma Is Maintained at Buy by D. Boral Capital

Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study

MT Newswires Live

BRIEF-Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort

Estrella Immunopharma completes first dose cohort in STARLIGHT trial

Estrella Immunopharma Completes First Dose Cohort in Starlight-1 Trial and Receives Approval to Initiate Higher Dose Cohort

THOMSON REUTERS

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Initiated at Buy by D. Boral Capital

Estrella Immunopharma initiated with a Buy at D. Boral Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ESLA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ESLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ESLA\",,,,,undefined,":{"symbol":"ESLA","market":"US","secType":"STK","nameCN":"Estrella Immunopharma","latestPrice":0.92,"timestamp":1750708800000,"preClose":0.99,"halted":0,"volume":11605,"hourTrading":{"tag":"盘后","latestPrice":0.92,"preClose":0.92,"latestTime":"17:59 EDT","volume":51,"amount":44.9503,"timestamp":1750715976837},"delay":0,"floatShares":9912119,"shares":36165589,"eps":-0.242472,"marketStatus":"Closed","change":-0.07,"latestTime":"06-23 16:00:00 EDT","open":0.93,"high":0.9899,"low":0.8971,"amount":11069.8279978,"amplitude":0.093737,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.242472,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750752000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":0.99,"postHourTrading":{"tag":"盘后","latestPrice":0.92,"preClose":0.92,"latestTime":"17:59 EDT","volume":51,"amount":44.9503,"timestamp":1750715976837},"volumeRatio":0.270845},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ESLA\",,,,,undefined,":{"symbol":"ESLA","floatShares":9912119,"roa":"-100.93%","roe":"-268.50%","lyrEps":-0.121236,"volumeRatio":0.270845,"shares":36165589,"dividePrice":0,"high":0.9899,"amplitude":0.093737,"preClose":0.99,"low":0.8971,"week52Low":0.63,"pbRate":"-18.17","week52High":3.23,"institutionHeld":0,"latestPrice":0.92,"eps":-0.242472,"divideRate":0,"volume":11605,"delay":0,"ttmEps":-0.242472,"open":0.93,"prevYearClose":1.2,"prevWeekClose":0.99,"prevMonthClose":1.0096,"prevQuarterClose":0.927,"fiveDayClose":0.96,"twentyDayClose":1,"sixtyDayClose":0.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ESLA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541702700","title":"Estrella Immunopharma Partners with Baylor Research Institute to Expand STARLIGHT-1 Trial for B-cell Non-Hodgkin’s Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2541702700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541702700?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:01","pubTimestamp":1749124887,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced a new partnership with the Baylor Research Institute, operating as Baylor Scott & White Research Institute in Dallas, Texas. This collaboration marks a significant development in Estrella's ongoing STARLIGHT-1 Phase I/II clinical trial, which is focused on evaluating EB103, a CD19-Redirected ARTEMIS T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma . The partnership aims to expand the clinical footprint, accelerating the development of EB103 and enhancing patient access to this promising therapy. The Baylor Research Institute will serve as a new clinical site, now open for patient enrollment, furthering Estrella's mission to deliver safer and more effective treatments for NHL patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL4b9kZr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2541027235","title":"Estrella Immunopharma Announces Activation of Additional Site for Phase I/Ii Starlight-1 Trial in B-Cell Non-Hodgkin’s Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2541027235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541027235?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:00","pubTimestamp":1749124802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nTUA54BLWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2540708805","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2540708805","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540708805?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:57","pubTimestamp":1748962620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2025 10:57 ET (14:57 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2540779187","title":"Estrella Immunopharma Secures $3.35 Million Through Private Equity Placement to Advance Cancer Therapy Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2540779187","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540779187?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:01","pubTimestamp":1748952060,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire  on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL6Cx6hL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2540796447","title":"Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540796447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540796447?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:00","pubTimestamp":1748952002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUAZZ58F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2539268497","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2539268497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539268497?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:56","pubTimestamp":1748523360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2025 08:56 ET (12:56 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2539257741","title":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin’s Lymphomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2539257741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539257741?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:01","pubTimestamp":1748520090,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Advances STARLIGHT-1 Trial, Begins Dosing Second Cohort with EB103 for Advanced B-Cell Non-Hodgkin's Lymphomas. Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL1FsY2c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2539257785","title":"Estrella Immunopharma Initiates Second Cohort and Doses First Patient in Starlight-1 Trial of Eb103 in Advanced B-Cell Non-Hodgkin’s Lymphomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2539257785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539257785?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:01","pubTimestamp":1748520060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA3DRYFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2513902012","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2513902012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513902012?lang=en_us&edition=fundamental","pubTime":"2025-02-22 00:58","pubTimestamp":1740157080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 21, 2025 11:58 ET (16:58 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2513924812","title":"Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2513924812","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513924812?lang=en_us&edition=fundamental","pubTime":"2025-02-22 00:10","pubTimestamp":1740154215,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma (ESLA) said Friday it has completed the first dose group in its ongoing phase I/II clinical trial evaluating EB103 in adult patients with relapsed/refractory B-cell non-Hodgkin l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2513129368","title":"BRIEF-Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2513129368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513129368?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:08","pubTimestamp":1740146889,"startTime":"0","endTime":"0","summary":"BRIEF-Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose CohortFeb 21 (Reuters) - Estrella Immunopharma Inc ESLA.O:ESTRELLA IMMUNOPHAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC0YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2513298026","title":"Estrella Immunopharma completes first dose cohort in STARLIGHT trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2513298026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513298026?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:55","pubTimestamp":1740146136,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma (ESLA) announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Fol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-first-dose-cohort-in-starlight-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-first-dose-cohort-in-starlight-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2513260233","title":"Estrella Immunopharma Completes First Dose Cohort in Starlight-1 Trial and Receives Approval to Initiate Higher Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2513260233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513260233?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:30","pubTimestamp":1740144638,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250221:nFWN3PC0YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2513298565","title":"Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2513298565","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513298565?lang=en_us&edition=fundamental","pubTime":"2025-02-21 21:30","pubTimestamp":1740144600,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., February 21, 2025----Estrella Immunopharma, Inc.  , a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board  has approved the initiation of the second dose cohort, which will administer 5 million receptor-positive T cells per kilogram of body weight of EB103 CD19-Redirected ARTEMIS T-cell therapy.Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/estrella-immunopharma-completes-first-dose-133000768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ESLA","BK4139","ESLAW"],"gpt_icon":0},{"id":"2512305394","title":"Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512305394","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512305394?lang=en_us&edition=fundamental","pubTime":"2025-02-20 05:46","pubTimestamp":1740001560,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., February 19, 2025----Estrella Immunopharma, Inc.  , a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC , a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00.D. Boral Capital’s analysis focuses on the development of EB103 in B-cell Non-Hodgkin’s Lymphoma, emphasizing Estrella’s ARTEMIS T-cell engineering platform that utilizes cellular mechanisms which closely resemble those of endogenous T-cell receptors, producing a more natural and regulated immune response.The derived 12-month price target of $16.00 underscores market confidence in Estrella’s potential to capture significant market share in immuno-oncology.The models incorporate a 30% probability of success along with a 30% discount rate, reflecting the early stage of Estrella’s clini","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/estrella-immunopharma-inc-nasdaq-esla-214600801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","ESLA","ESLAW",".IXIC"],"gpt_icon":0},{"id":"2512417151","title":"Estrella Immunopharma Initiated at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512417151","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512417151?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:21","pubTimestamp":1739881260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2025 07:21 ET (12:21 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2512151669","title":"Estrella Immunopharma initiated with a Buy at D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2512151669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512151669?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:16","pubTimestamp":1739881005,"startTime":"0","endTime":"0","summary":"D. Boral Capital analyst Jason Kolbert initiated coverage of Estrella Immunopharma (ESLA) with a Buy rating and $16 price target The firm says Estr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-initiated-with-a-buy-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-initiated-with-a-buy-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ESLA"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ESLA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ESLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ESLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1739937600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ESLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ESLA","date":"2025-06-20","current":-3.80443,"percent":0.883085,"low":-10.568666,"twenty":-5.54228,"median":-4.595239,"eighty":-4.043395,"high":-3.104323,"avg":-4.878674,"sd":1.167286,"marketCap":33684629},"quantilePoints":[{"date":"2023-10-13","current":-4.972461,"twenty":-6.796753,"median":-5.384194,"eighty":-5.200498,"marketCap":55265934},{"date":"2023-10-20","current":-4.346628,"twenty":-5.624899,"median":-4.845774,"eighty":-4.503973,"marketCap":48310170},{"date":"2023-10-27","current":-4.814103,"twenty":-5.358857,"median":-4.766595,"eighty":-4.395592,"marketCap":53505872},{"date":"2023-11-03","current":-4.877446,"twenty":-5.358857,"median":-4.877446,"eighty":-4.546793,"marketCap":54209897},{"date":"2023-11-10","current":-4.085653,"twenty":-5.257507,"median":-4.829938,"eighty":-4.367404,"marketCap":45409589},{"date":"2023-11-17","current":-3.800607,"twenty":-5.219501,"median":-4.560729,"eighty":-4.142662,"marketCap":42241478},{"date":"2023-11-24","current":-4.914497,"twenty":-5.067477,"median":-4.560729,"eighty":-4.117325,"marketCap":49633737},{"date":"2023-12-01","current":-5.785861,"twenty":-5.257507,"median":-4.829938,"eighty":-4.244012,"marketCap":58434045},{"date":"2023-12-08","current":-4.18255,"twenty":-5.193333,"median":-4.719087,"eighty":-4.244012,"marketCap":42241478},{"date":"2023-12-15","current":-4.356823,"twenty":-5.067477,"median":-4.653087,"eighty":-4.244012,"marketCap":44001540},{"date":"2023-12-22","current":-4.321969,"twenty":-5.053915,"median":-4.560729,"eighty":-4.244012,"marketCap":43649527},{"date":"2023-12-29","current":-4.008277,"twenty":-5.005043,"median":-4.502348,"eighty":-4.203463,"marketCap":40481416},{"date":"2024-01-05","current":-4.043132,"twenty":-4.967839,"median":-4.461387,"eighty":-4.18255,"marketCap":40833429},{"date":"2024-01-12","current":-3.520313,"twenty":-4.949351,"median":-4.397024,"eighty":-4.086666,"marketCap":35553244},{"date":"2024-01-19","current":-3.555168,"twenty":-4.949351,"median":-4.37517,"eighty":-4.043132,"marketCap":35905256},{"date":"2024-01-26","current":-4.217405,"twenty":-4.914497,"median":-4.391678,"eighty":-4.043132,"marketCap":42593490},{"date":"2024-02-02","current":-4.217405,"twenty":-4.914497,"median":-4.356823,"eighty":-4.022309,"marketCap":42593490},{"date":"2024-02-09","current":-4.008626,"twenty":-4.879642,"median":-4.356475,"eighty":-4.008626,"marketCap":40484936},{"date":"2024-02-16","current":-3.79915,"twenty":-4.877446,"median":-4.314662,"eighty":-4.008277,"marketCap":38369342},{"date":"2024-02-23","current":-4.421106,"twenty":-4.852108,"median":-4.351551,"eighty":-4.008277,"marketCap":36976978},{"date":"2024-03-01","current":-4.46488,"twenty":-4.845774,"median":-4.356823,"eighty":-4.008556,"marketCap":37343087},{"date":"2024-03-08","current":-4.683308,"twenty":-4.845774,"median":-4.37517,"eighty":-4.008626,"marketCap":39169969},{"date":"2024-03-15","current":-4.508653,"twenty":-4.845774,"median":-4.391678,"eighty":-4.019572,"marketCap":37709196},{"date":"2024-03-22","current":-4.727519,"twenty":-4.845774,"median":-4.421106,"eighty":-4.038967,"marketCap":39539739},{"date":"2024-03-28","current":-5.471666,"twenty":-4.878324,"median":-4.421106,"eighty":-4.043132,"marketCap":45763587},{"date":"2024-04-05","current":-4.990159,"twenty":-4.946386,"median":-4.434042,"eighty":-4.068645,"marketCap":41736391},{"date":"2024-04-12","current":-4.771293,"twenty":-4.947572,"median":-4.461387,"eighty":-4.088693,"marketCap":39905848},{"date":"2024-04-19","current":-4.508653,"twenty":-4.946386,"median":-4.46488,"eighty":-4.106683,"marketCap":37709196},{"date":"2024-04-26","current":-4.552426,"twenty":-4.946123,"median":-4.508653,"eighty":-4.135548,"marketCap":38075304},{"date":"2024-05-03","current":-4.604954,"twenty":-4.927077,"median":-4.543309,"eighty":-4.168608,"marketCap":38514635},{"date":"2024-05-10","current":-4.683746,"twenty":-4.914497,"median":-4.525981,"eighty":-4.18255,"marketCap":39173630},{"date":"2024-05-17","current":-6.309978,"twenty":-4.927077,"median":-4.552426,"eighty":-4.18255,"marketCap":38441413},{"date":"2024-05-24","current":-6.009503,"twenty":-4.949351,"median":-4.552645,"eighty":-4.18255,"marketCap":36610870},{"date":"2024-05-31","current":-5.254478,"twenty":-5.016423,"median":-4.56334,"eighty":-4.196492,"marketCap":32011137},{"date":"2024-06-07","current":-5.573329,"twenty":-5.126143,"median":-4.595762,"eighty":-4.217405,"marketCap":33953631},{"date":"2024-06-14","current":-5.672448,"twenty":-5.245388,"median":-4.604954,"eighty":-4.217405,"marketCap":34557478},{"date":"2024-06-21","current":-5.254478,"twenty":-5.254478,"median":-4.639973,"eighty":-4.217405,"marketCap":32011137},{"date":"2024-06-28","current":-5.553028,"twenty":-5.257507,"median":-4.639973,"eighty":-4.217405,"marketCap":33829952},{"date":"2024-07-05","current":-6.836793,"twenty":-5.380881,"median":-4.661859,"eighty":-4.222726,"marketCap":41650855},{"date":"2024-07-12","current":-8.120557,"twenty":-5.46684,"median":-4.674942,"eighty":-4.245731,"marketCap":49471758},{"date":"2024-07-15","current":-8.478817,"twenty":-5.484657,"median":-4.679369,"eighty":-4.24745,"marketCap":51654336},{"date":"2024-08-02","current":-10.568666,"twenty":-5.500483,"median":-4.681339,"eighty":-4.24917,"marketCap":64386038},{"date":"2024-08-09","current":-8.299687,"twenty":-5.526159,"median":-4.683746,"eighty":-4.266453,"marketCap":50563047},{"date":"2024-08-16","current":-8.419107,"twenty":-5.589093,"median":-4.694558,"eighty":-4.282332,"marketCap":51290573},{"date":"2024-08-23","current":-7.881717,"twenty":-5.717813,"median":-4.727519,"eighty":-4.286974,"marketCap":48016706},{"date":"2024-08-30","current":-6.896503,"twenty":-6.017985,"median":-4.738462,"eighty":-4.287114,"marketCap":42014618},{"date":"2024-09-06","current":-6.329258,"twenty":-6.201587,"median":-4.792698,"eighty":-4.288183,"marketCap":38558870},{"date":"2024-09-13","current":-7.045778,"twenty":-6.309738,"median":-4.815066,"eighty":-4.296814,"marketCap":42924025},{"date":"2024-09-20","current":-5.76261,"twenty":-6.309738,"median":-4.815066,"eighty":-4.313201,"marketCap":35106760},{"date":"2024-09-27","current":-5.791271,"twenty":-6.293445,"median":-4.845774,"eighty":-4.331833,"marketCap":35281366},{"date":"2024-10-04","current":-5.494176,"twenty":-6.293445,"median":-4.868142,"eighty":-4.350567,"marketCap":40171894},{"date":"2024-10-11","current":-4.148845,"twenty":-6.216784,"median":-4.858839,"eighty":-4.350567,"marketCap":30335209},{"date":"2024-10-18","current":-4.157755,"twenty":-6.122441,"median":-4.845774,"eighty":-4.288183,"marketCap":30400352},{"date":"2024-10-25","current":-4.212202,"twenty":-6.099645,"median":-4.815066,"eighty":-4.286905,"marketCap":30798452},{"date":"2024-10-31","current":-4.032032,"twenty":-6.085858,"median":-4.815066,"eighty":-4.286835,"marketCap":29481103},{"date":"2024-11-08","current":-3.964716,"twenty":-6.030708,"median":-4.792698,"eighty":-4.245731,"marketCap":28988907},{"date":"2024-11-15","current":-4.157755,"twenty":-6.026467,"median":-4.727519,"eighty":-4.217405,"marketCap":30400352},{"date":"2024-11-22","current":-3.652759,"twenty":-6.001802,"median":-4.723303,"eighty":-4.18255,"marketCap":32209897},{"date":"2024-11-29","current":-4.656782,"twenty":-5.970998,"median":-4.694558,"eighty":-4.18255,"marketCap":41063331},{"date":"2024-12-06","current":-5.005528,"twenty":-5.961427,"median":-4.719087,"eighty":-4.18255,"marketCap":44138559},{"date":"2024-12-13","current":-5.066661,"twenty":-5.907942,"median":-4.727519,"eighty":-4.18255,"marketCap":44677628},{"date":"2024-12-20","current":-4.513181,"twenty":-5.895445,"median":-4.727519,"eighty":-4.18255,"marketCap":39797061},{"date":"2024-12-27","current":-4.800383,"twenty":-5.891211,"median":-4.759354,"eighty":-4.202312,"marketCap":42329601},{"date":"2025-01-03","current":-4.595649,"twenty":-5.831182,"median":-4.759354,"eighty":-4.210222,"marketCap":40524262},{"date":"2025-01-10","current":-4.55421,"twenty":-5.791868,"median":-4.759354,"eighty":-4.214283,"marketCap":40158853},{"date":"2025-01-17","current":-4.808589,"twenty":-5.791868,"median":-4.765324,"eighty":-4.217405,"marketCap":42401960},{"date":"2025-01-24","current":-4.841412,"twenty":-5.791749,"median":-4.765324,"eighty":-4.217405,"marketCap":42691393},{"date":"2025-01-31","current":-4.595239,"twenty":-5.790189,"median":-4.759354,"eighty":-4.217405,"marketCap":40520644},{"date":"2025-02-07","current":-4.718325,"twenty":-5.781211,"median":-4.75438,"eighty":-4.222726,"marketCap":41606019},{"date":"2025-02-14","current":-4.636268,"twenty":-5.75842,"median":-4.727519,"eighty":-4.245731,"marketCap":40882436},{"date":"2025-02-21","current":-6.113309,"twenty":-5.785861,"median":-4.749406,"eighty":-4.252608,"marketCap":53906929},{"date":"2025-02-28","current":-3.938776,"twenty":-5.785861,"median":-4.75438,"eighty":-4.252608,"marketCap":34731981},{"date":"2025-03-07","current":-4.061863,"twenty":-5.76261,"median":-4.727519,"eighty":-4.217405,"marketCap":35817355},{"date":"2025-03-14","current":-4.184949,"twenty":-5.741662,"median":-4.718911,"eighty":-4.212202,"marketCap":36902729},{"date":"2025-03-21","current":-3.781635,"twenty":-5.692164,"median":-4.717095,"eighty":-4.184949,"marketCap":33346319},{"date":"2025-03-28","current":-3.800136,"twenty":-5.672448,"median":-4.683746,"eighty":-4.18255,"marketCap":33646606},{"date":"2025-04-04","current":-3.839558,"twenty":-5.66199,"median":-4.683746,"eighty":-4.157755,"marketCap":33995653},{"date":"2025-04-11","current":-3.717019,"twenty":-5.653341,"median":-4.678332,"eighty":-4.145266,"marketCap":32910685},{"date":"2025-04-17","current":-3.41639,"twenty":-5.652863,"median":-4.673905,"eighty":-4.117991,"marketCap":30248898},{"date":"2025-04-25","current":-3.921251,"twenty":-5.627318,"median":-4.661859,"eighty":-4.100129,"marketCap":34718965},{"date":"2025-05-02","current":-4.656485,"twenty":-5.620962,"median":-4.656633,"eighty":-4.100129,"marketCap":41228771},{"date":"2025-05-09","current":-4.738178,"twenty":-5.614383,"median":-4.656485,"eighty":-4.103875,"marketCap":41952083},{"date":"2025-05-16","current":-3.800286,"twenty":-5.606051,"median":-4.639973,"eighty":-4.100129,"marketCap":33999270},{"date":"2025-05-23","current":-3.448008,"twenty":-5.579539,"median":-4.636268,"eighty":-4.061863,"marketCap":36165589},{"date":"2025-05-30","current":-4.166329,"twenty":-5.561148,"median":-4.636268,"eighty":-4.061535,"marketCap":36888900},{"date":"2025-06-06","current":-4.329714,"twenty":-5.553028,"median":-4.610297,"eighty":-4.04971,"marketCap":38335524},{"date":"2025-06-13","current":-4.125482,"twenty":-5.553028,"median":-4.595762,"eighty":-4.04971,"marketCap":36527244},{"date":"2025-06-20","current":-3.80443,"twenty":-5.54228,"median":-4.595239,"eighty":-4.043395,"marketCap":33684629}],"updateTime":1750705345591}}}